KETAMINE BLUE CAPSULE - AN OVERVIEW

No clinically considerable differences within the pharmacokinetics of midazolam (CYP3A4 substrate) or its metabolite 1-hydroxymidazolam were being observed when utilised concomitantly with single or a number of doses of lumateperone in individuals with schizophrenia.                                         �